Tandem Health raises $100M for Europe's AI clinic operating system

Share
Tandem Health raises $100M for Europe's AI clinic operating system

Monday afternoon's money went into the least glamorous part of the AI stack — the part with a regulator attached. Stockholm's Tandem Health landed Europe's biggest clinical-AI round to date, Waymo opened its doors in Las Vegas, and Akuity made the case that agents need an identity before they get a production deploy.

Tandem Health raised a $100M Series B led by the Scaleup Europe Fund, the €5 billion vehicle the European Commission put EQT in charge of this year. It is the fund's first healthcare investment and only its second overall — the first was $400 million into Lovable — and it takes Tandem's total raised to $160 million. Kinnevik, Northzone, Amino Collective and the Visionaries Club, which backed the company's $50M Series A in 2025, also participated. What Tandem sells is not a note-taker: an AI scribe that listens to consultations, a coding assistant that suggests billing codes, and clinical decision support, all three of which the company says are certified as Class IIa medical devices under the EU's Medical Device Regulation — a slower, more expensive path than most of its competitors take. That bet is now deployed across more than 10,000 care organisations in 14 European markets, including Ramsay Santé, Humanitas and the NHS, with roughly 175 staff of whom more than 75 are clinicians. The macro case is a demographic one: the WHO projects Europe is short 1.6 million health and social care workers this year, heading toward 4 million by 2030, and clinical documentation is a segment forecast to grow from about $1.05 billion in 2026 to $10.5 billion by 2034. The roadmap is to weld patient-flow management onto the scribe and call the result an AI Clinic Operating System. My read: the moat here is the certification, not the model — Abridge has raised roughly $780 million at a $5.3 billion valuation and is still rebuilt around US reimbursement rules, while Nabla and Heidi Health chase European clinics on speed and price. EQT choosing a compliance-heavy health company over a faster-growing one is the tell that public money in European AI is being spent where regulation is the product. The open question is whether hospital procurement moves as slowly as the certification process promises protection from.


Waymo opened its robotaxi service to the public in Las Vegas on Monday, its 15th market. Riders must request an invite and wait for an access code, following the playbook the Alphabet-owned company has used in 14 other cities, with general availability typically arriving within a month or two of launch. It is starting with dozens of its new Ojai minivans, serving the Strip south of Highway 589 and into Boulder Junction. Nevada has authorised Waymo to operate up to 1,000 autonomous vehicles over the next year, against up to 5,000 for Tesla and up to 1,000 for Uber, which will run through Motional and Zoox — permits that would put as many as 8,000 robotaxis in the county within twelve months. Nobody expects those numbers to be hit: Waymo's entire global fleet is a little over 4,000 vehicles spread across more than a dozen cities, and Tesla's Cybercab chief engineer told state regulators in August he'd consider roughly 2,500 a good outcome next year. Even so, Las Vegas is where the density math gets interesting, and it's a different distribution problem from Austin or Miami — a tourist-heavy, ride-hail-saturated strip where winning riders means beating the app already on their phone.


Akuity launched an Agentic Control Plane that routes every agent request through a human identity instead of a shared service account. The argument is that agents are already operating inside production environments, largely through open-source MCP servers that hand over raw access with no identity carried through and no audit trail of what the agent touched. Akuity's control plane authenticates an agent as the specific person who connected it, so that person's existing permissions travel across every managed instance and cluster — no separate credentials to issue or rotate — with a policy layer above it that can block sensitive production actions the user is otherwise cleared to perform. Agents reach the operational record of the pipeline itself: deployment history, cluster health and change lineage down to the commit behind any given deployment. Major League Baseball is an early user; principal DevOps engineer Michael Goodness said in a statement that the control plane surfaced more than 100 degraded applications within hours of being switched on and traced a systemic issue to root cause in under 10 minutes. Akuity's co-founder and CEO Hong Wang frames the next phase as infrastructure change delivery rather than code generation — the winners being whoever gives agents a reliable, gated path to production.

What to watch: whether Scaleup Europe Fund's second and third deployments follow the same compliance-first pattern, which would tell you this was a sector thesis rather than one good deal.

If a Class IIa certification is the actual moat in clinical AI, does that make model quality a commodity — or does the first US lab to clear EU medical-device rules eat this market anyway?

Source: Tech.eu via Techmeme

Get SiliconNoon in your inbox

One email a day with the AI stories that matter — what happened, the numbers, and why it matters. No spam, unsubscribe in one click.

Read more

Altis Labs raises $25M to make an AI scan read a trial endpoint

Altis Labs raises $25M to make an AI scan read a trial endpoint

A cancer-trial startup wants its model's reading of a CT scan to be the number a drug is judged by — and Apple's Siri home hub is already in employees' hands. Altis Labs raised $25 million to make an AI reading of a CT scan the thing a cancer trial is measured against. The round, announced September 17 and co-led by OrbiMed and Qiming Venture Partners USA, funds a company whose product is not a drug and not a chatbot: IPRO, a model that reads routine CT scans taken during oncology trials and…

Enveda raises $311 million to turn nature's chemistry into drugs

Enveda raises $311 million to turn nature's chemistry into drugs

A biotech that reads molecules out of plants and microbes just raised the largest round of the week — and a 2.5B open model showed up to embarrass models twice its size. Enveda has raised $311 million in a Series E led by Catalio Capital Management, at a $2 billion valuation that doubles what the company was worth twelve months ago. The Boulder, Colorado company does not design molecules from scratch; it searches for them.

Amodei: AI will cure most human diseases within a decade

Amodei: AI will cure most human diseases within a decade

Two stories out of the labs' pre-IPO week: Anthropic's CEO staked public trust on a medical moonshot, and OpenAI kept losing the engineers who built it. Dario Amodei published his most personal case for Anthropic yet — and set a deadline: AI will cure most human diseases within five to ten years, with early results promised "in the coming months." In a rare long-form post, Anthropic's CEO answered Silicon Valley's loudest critic, investor Gavin Baker, who had said (citing "multiple credible…

Agents that run for weeks made Temporal a $12.55 billion company

Agents that run for weeks made Temporal a $12.55 billion company

Two funding rounds on opposite ends of the AI stack today: one selling the plumbing that keeps agents alive, one selling music toys that refuse to prompt a model at all. Temporal raised $550 million in a Series E at a $12.55 billion valuation, and the reason it gives is duration. A year ago the company says most of its customer conversations were about payments, onboarding and fulfillment; now customers want agents that run for days, weeks or months without losing state.

Cornelis raised $205 million. Its pitch: the network, not the chip

Cornelis raised $205 million. Its pitch: the network, not the chip

Monday's news ran from the inside of the AI rack to the inside of the White House — a networking challenger that says the GPUs are not the bottleneck, a private Altman-Trump meeting that surfaced the same day the two split publicly on slowing down, and a mathematician's attempt to say what the profession should be for. Cornelis Networks announced roughly $205 million in funding alongside Active Compute Fabric, an open networking architecture that puts programmable compute inside the fabric…

Anthropic tells investors it will be profitable for a second quarter

Anthropic tells investors it will be profitable for a second quarter

The week AI's biggest labs spent asking for permission to slow down ended with one of them telling shareholders the money is very good — and the number attached to that claim reframes the entire pacing debate. Anthropic has told shareholders its adjusted operating income will be positive for a second straight quarter, with gross margins above 80%, according to the Financial Times, which sourced the report to multiple people with knowledge of the matter.